文献类型：期刊文献

英文题名：Obacunone ameliorates high-fat diet-induced MAFLD by regulating the PPARγ-FABP1/CD36 axis and the gut-liver crosstalk

作者：Wang, Xuewen[1,2];Hong, Jiaming[1];Liang, Rui[1];Bao, Shuoqiang[2];Li, Lingru[3];Wang, Jing[2];Feng, Juan[1]

第一作者：王雄伟;Wang, Xuewen

通信作者：Feng, J[1];Wang, J[2];Li, LR[3]

机构：[1]Shenzhen Technol Univ, Coll Hlth Sci & Environm Engn, 3002 Lantian Rd, Shenzhen 518118, Peoples R China;[2]Gansu Univ Chinese Med, Sch Publ Hlth, 35 Dingxi East Rd, Lanzhou 730000, Peoples R China;[3]Beijing Univ Chinese Med, Natl Inst Tradit Chinese Med Constitut & Prevent T, 11 North Third Ring East Rd, Beijing 100029, Peoples R China

第一机构：Shenzhen Technol Univ, Coll Hlth Sci & Environm Engn, 3002 Lantian Rd, Shenzhen 518118, Peoples R China

通信机构：[1]corresponding author), Shenzhen Technol Univ, Coll Hlth Sci & Environm Engn, 3002 Lantian Rd, Shenzhen 518118, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Sch Publ Hlth, 35 Dingxi East Rd, Lanzhou 730000, Peoples R China;[3]corresponding author), Beijing Univ Chinese Med, Natl Inst Tradit Chinese Med Constitut & Prevent T, 11 North Third Ring East Rd, Beijing 100029, Peoples R China.|[10735e9d5e7087247e71b]甘肃中医药大学公共卫生学院;[10735]甘肃中医药大学;

年份：2025

卷号：147

外文期刊名：PHYTOMEDICINE

收录：;Scopus(收录号：2-s2.0-105013757569);WOS:【SCI-EXPANDED(收录号:WOS:001562191500002)】；

基金：This work was financially supported by the National Natural Science Foundation of China (No. 82204759), the Shenzhen Science and Technology Program (No. JCYJ20240813113239051), and the Natural Science Foundation of Gansu Province (2025JRRA931), and Key Laboratory of Chemistry and Quality for TCM of the College of Gansu Province (zzy-2024-06) .

语种：英文

外文关键词：MAFLD; Obacunone; PPAR gamma; Fatty acid uptake; Gut-liver crosstalk

摘要：Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a global health challenge with limited treatment options. Obacunone (Oba), a natural triterpenoid with anti-inflammatory and antioxidant properties, may address metabolic disorders, but its role in MAFLD is unclear. Purpose: To investigate Oba's effects in high-fat diet (HFD)-induced MAFLD mice and free fatty acid (FFA)stimulated HepG2 cells. Methods: Liver lipid metabolism and function were assessed using hepatic TG, NEFA, SOD, ALT, and AST levels. Molecular mechanisms were explored with transcriptomic profiling, dual-luciferase reporter assay, ubiquitinproteasome system, co-immunoprecipitation, and molecular docking. Gut-liver axis dynamics were evaluated by 16S rDNA sequencing, LPS/cytokine detectiondetecction, and ZO-1 immunohistochemistry. Antiinflammatory effects were confirmed in TNF-alpha-stimulated SW620 cells, and fecal metabolomics analysis was performed to screen microbial-derived bioactive metabolites. Results: Oba reduced hepatic TG, NEFA, ALT, and AST levels, while increasing hepatic SOD activity, exhibiting anti-steatotic, anti-oxidative, and hepatic protective effects. Mechanistically, Oba suppressed lipid accumulation via ubiquitin-proteasome-mediated degradation of PPAR gamma, downregulating FABP1 and CD36. Molecular docking and co-immunoprecipitation showed Oba promoted PPAR gamma ubiquitination without disrupting PPAR gamma: RXR alpha heterodimerization. Oba improved gut microbiota, repaired intestinal barrier integrity by upregulating ZO-1, and reduced serum LPS and inflammatory cytokines (TNF-alpha, IL-6). In TNF-alpha-stimulated SW620 cells, Oba inhibited NF-kappa B activation. 16S rDNA sequencing analysis revealed that Oba could regulate the composition of intestinal microbiota. Specifically, Oba effectively restored the diversity of intestinal microbial communities, significantly decreased the abundance of Firmicutes, and simultaneously increased the proportion of Bacteroidetes, thereby optimizing the composition of microbiota at the phylum level. At the genus level, Oba reduced the abundance of genera such as Ralstonia, Dialister, and Elizabethkingia, while up-regulated the abundance of Eubacterium_ventriosum_group, Eubacterium_xylanophilum_group, and Akkermansia. Fecal metabolomics revealed Oba restored beneficial metabolites like ergothioneine, correlated with improved liver markers. Conclusion: Oba ameliorates MAFLD through dual mechanisms: modulating the PPAR gamma-FABP1/CD36 axis to suppress hepatic lipid uptake and rebalancing gut-liver crosstalk via microbiota-derived metabolites. These findings support Oba as a promising multi-target therapeutic candidate for MAFLD.